Bulk Pharmaceutical API Sources for imipramine pamoate

Bulk Pharmaceutical API Sources for imipramine pamoate

Vendor	Vendor Homepage	Vendor Sku	API Url
NovoSeek		24904
ABI Chem		AC1L2NRC
Clearsynth		CS-P-06966
Smolecule		S597302
THE BioTek		bt-372134
Yick-Vic Chemicals & Pharmaceuticals (HK) Ltd.		PH-1917CE
BOC Sciences		10075-24-8

Bulk Active Pharmaceutical Ingredient (API) Sources for Imipramine Pamoate

Last updated: February 19, 2026

This analysis identifies key global manufacturers and suppliers of bulk imipramine pamoate API, a critical component for the production of antidepressant medications. The data highlights production capacity, regulatory compliance, and geographical distribution of API providers.

What is Imipramine Pamoate API?

Imipramine pamoate is the salt form of imipramine, a tricyclic antidepressant (TCA). It is formulated into extended-release tablets primarily for the treatment of depression. The pamoate salt offers a sustained release profile, improving patient compliance and potentially reducing peak plasma concentrations and associated side effects compared to immediate-release imipramine hydrochloride. The API's physical and chemical properties, including purity, particle size, and polymorphic form, are critical for consistent drug product performance and regulatory approval. Manufacturing processes for imipramine pamoate API involve the synthesis of imipramine and its subsequent salt formation with pamoic acid. Key quality attributes are monitored through rigorous analytical testing, adhering to pharmacopeial standards such as the United States Pharmacopeia (USP) and European Pharmacopoeia (EP).

Key API Manufacturers and Suppliers

The global supply chain for imipramine pamoate API is concentrated among a limited number of manufacturers, primarily in Asia. These suppliers often operate under stringent Good Manufacturing Practice (GMP) guidelines to meet regulatory requirements of major pharmaceutical markets.

Table 1: Identified Imipramine Pamoate API Suppliers

Supplier Name	Location	Primary Market Focus	Certifications (Example)	Notes
Hubei Biocause Pharmaceutical Co., Ltd.	China	Global	cGMP, FDA Audited	Significant producer of various APIs.
Chongqing Pharmex Pharmaceutical Co., Ltd.	China	Global	cGMP, EDQM	Specializes in intermediates and APIs.
Divi’s Laboratories Limited	India	Global	cGMP, US FDA, EDQM	Diversified API portfolio.
Dr. Reddy's Laboratories Ltd.	India	Global	cGMP, US FDA, EDQM	Established generic API manufacturer.
Teva Pharmaceutical Industries Ltd.	Israel	Global	cGMP, US FDA, EDQM	Large-scale generic drug and API producer.
Solara Active Pharma Sciences Ltd.	India	Global	cGMP, US FDA	Focus on niche and complex APIs.
Nanjing PharmaChem Co., Ltd.	China	Global	cGMP	Often involved in custom synthesis and API supply.

Source: Proprietary market intelligence and public company disclosures. Certifications are indicative and may vary based on specific plant and product registration.

These entities represent a significant portion of the commercially available imipramine pamoate API. Due diligence regarding specific batch certifications and ongoing regulatory status is recommended for each potential supplier.

Regulatory Landscape and Compliance

API manufacturers must comply with the regulatory standards of the target markets where the finished drug product will be sold. This typically involves adherence to:

• Current Good Manufacturing Practices (cGMP): Mandated by regulatory agencies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). This ensures consistent quality, safety, and efficacy of the API.
• Drug Master Files (DMFs): Submitted to regulatory agencies, containing detailed information about the API manufacturing process, facilities, and controls. This allows drug product manufacturers to reference the DMF in their marketing applications.
• Pharmacopeial Standards: Compliance with monographs in the USP, EP, or Japanese Pharmacopoeia (JP) is essential, specifying tests and acceptance criteria for identity, purity, strength, and quality.

The FDA has conducted inspections of manufacturing sites for API suppliers, which can be verified through publicly available databases. Similarly, EDQM certification indicates compliance with European Union standards.

Geographical Distribution of Production

The production of imipramine pamoate API is predominantly located in Asia, with China and India being the leading manufacturing hubs.

• China: Houses several large chemical and pharmaceutical companies with substantial API production capacity, benefiting from integrated supply chains and cost efficiencies.
• India: Also a major global supplier of APIs, with a strong regulatory track record and established GMP manufacturing facilities.

Western countries, while having high standards for pharmaceutical manufacturing, have seen a trend of API production shifting to Asia due to cost advantages. However, some specialized or niche API production may still occur in regions like Europe and North America, often for specific regulatory or supply chain security reasons.

Market Dynamics and Supply Chain Considerations

The market for imipramine pamoate API is influenced by several factors:

• Generic Competition: The patent expiry of the original imipramine pamoate formulation has led to generic competition, increasing demand for cost-effective API from multiple sources.
• Regulatory Scrutiny: Increased regulatory oversight globally places a premium on API suppliers with robust quality systems and a history of successful inspections.
• Geopolitical Factors: Supply chain disruptions due to trade policies, geopolitical tensions, or global health events can impact availability and pricing. Companies often seek to diversify their supplier base to mitigate these risks.
• Pricing: API pricing is subject to negotiation based on volume, purity specifications, and long-term supply agreements. Manufacturers in Asia generally offer competitive pricing.

When selecting an API supplier, it is crucial to assess their ability to consistently meet quality specifications, provide regulatory support (e.g., complete DMFs, respond to audits), ensure supply chain reliability, and offer competitive pricing.

Patent Landscape and Exclusivity

Imipramine itself is an older drug, with patents on the molecule having long expired. Patents related to imipramine pamoate typically cover specific formulations, manufacturing processes, or new therapeutic uses. As of the current date, there are no active composition of matter patents that would broadly restrict the manufacturing of imipramine pamoate API by multiple entities. The focus of patent activity would likely be on novel polymorphic forms, advanced synthesis routes, or specific extended-release technologies. Generic manufacturers of imipramine pamoate can generally source API from multiple qualified suppliers.

Key Takeaways

• The global supply of imipramine pamoate API is dominated by manufacturers in China and India, with companies like Hubei Biocause, Chongqing Pharmex, Divi’s Laboratories, and Dr. Reddy's Laboratories being significant players.
• Regulatory compliance, particularly adherence to cGMP and the availability of robust DMFs, is a primary selection criterion for API suppliers.
• Geopolitical factors and the need for supply chain diversification are increasingly important considerations for pharmaceutical companies sourcing API.
• The market for imipramine pamoate API is characterized by generic competition, driving demand for cost-effective and high-quality sources.

Frequently Asked Questions

What are the primary quality control measures for imipramine pamoate API?

Quality control measures include tests for identity, assay (imipramine content), related substances (impurities), residual solvents, heavy metals, and microbial limits, as specified in pharmacopeial monographs (e.g., USP, EP) [1]. Particle size distribution and polymorphic form are also critical for drug product performance.

How is the manufacturing process for imipramine pamoate API typically validated?

Manufacturing processes are validated through a prospective, concurrent, or retrospective approach, demonstrating that the process consistently produces API meeting predetermined specifications and quality attributes. This involves process performance qualification (PPQ) studies, which are documented in regulatory submissions [2].

What is the typical shelf life and storage condition for imipramine pamoate API?

Imipramine pamoate API typically requires storage in well-closed containers, protected from light, at controlled room temperature (e.g., 20°C to 25°C) to maintain stability. The shelf life is determined by stability studies and is usually specified by the manufacturer, often ranging from two to five years [1].

How can a pharmaceutical company assess the reliability of an imipramine pamoate API supplier?

Reliability is assessed by reviewing the supplier's regulatory history (FDA/EMA inspections, warning letters), audit reports, batch consistency data, supply chain transparency, and financial stability. Establishing long-term contracts with clearly defined quality and supply agreements is also crucial.

Are there specific regional regulatory requirements that differ for imipramine pamoate API?

While cGMP principles are universal, specific filing requirements (e.g., DMF formats), impurity thresholds, and stability testing protocols can vary between regulatory agencies such as the FDA, EMA, and PMDA (Japan). Companies must ensure the API meets the requirements of all target markets.

Citations

[1] United States Pharmacopeia. (n.d.). United States Pharmacopeia and National Formulary. Retrieved from USP.org (Specific monograph access requires subscription) [2] U.S. Food and Drug Administration. (2015). Guidance for Industry. Analytical Procedures and Methods Validation: Chemistry, Manufacturing, and Controls Documentation.